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ABSTRACT
We present a novel liquid array diagnostics 
(LAD) method, which enables rapid and 
inexpensive detection of microbial markers 
in a single-tube multiplex reaction. We 
evaluated LAD both on pure cultures, 
and on infant gut microbiota for a 15-plex 
reaction. LAD showed more than 80% 
accuracy of classification and a detection 
limit lower than 2% of the Illumina reads per 
sample. The results on the clinical dataset 
showed that there was a rapid decrease of 
staphylococci from 10-day- to 4-month-old 
children, a peak of bifidobacteria at 
4 months, and a peak of Bacteroides in 
2-year-old children, which is in accordance 
with findings described in the literature. 
Being able to detect up to 50 biomarkers, 
LAD is a suitable method for assays where 
high throughput is essential.
METHOD SUMMARY
Liquid array diagnostics use short DNA 
duplexes, where one of the oligonucle-
otides is labeled with a fluorophore and 
the other, upon the presence of target 
DNA, becomes labeled with a quencher 
molecule. The novelty of this method lies 
in the combination of many duplex melting 
profiles and several channels of detection 
on a qPCR instrument, to detect multiple 
events of fluorescence quenching in a 
single-tube multiplex reaction.
The field of gut microbiota analysis has, 
until now, been dominated by relatively 
small-scale explorative studies, with 
several contradicting f indings 
obscuring the truth in literature [1,2]. 
We are therefore at a stage where high-
throughput, low- cost , targeted 
approaches are needed in order to 
generalize knowledge, and to evaluate 
previous findings. Presently, the 
GA-map® platform (Genetic Analysis 
AS) is the only clinically validated tool 
designated for gut microbiota 
diagnostics. The GA-map method 
allows for the faster assessment of the 
abundance of microbial markers in a 
sample ,  compared with NGS 
techniques [1]. However, it is based on 
solid-phase hybridization, which 
creates a bottleneck in sample 
processing and renders the test 
relatively expensive.
In this article, we present liquid array 
diagnostics (LAD), a novel approach 
for detecting bacterial communities 
using real-time PCR instrumentation. 
LAD combines single nucleotide primer 
extension with high-resolution melting 
(HRM) in the concept of a liquid array. It 
does not require physical separation of the 
probes prior to detection, thus avoiding 
a bottleneck in sample processing and 
ensuring rapid results at very low running 
costs. Requiring only a qPCR instrument, 
it has great potential for use as a routine 
tool for diagnostics by reporting multiple 
gut microbial markers in a single-tube 
multiplex reaction within a working day. 
A schematic outline of LAD is provided 
in Figure 1. 
We evaluated LAD both on pure 
cultures, and on infant gut microbiota. 
The rationale for investigating the infant 
gut microbiota is that their composition 
and development are well described by 
many studies [2–4], and that we can 
utilize an already designed and validated 
GA-map probe set [5]. Furthermore, the 
development of the gut microbiota 
during infancy is crucial for health later 
in life. However, large-scale validation 
studies are required before knowledge 
about the gut microbiota can be utilized 
in clinical practice.
We present results demonstrating 
the sensitivity and specificity of LAD, in 
addition to exemplifying its utility on a 
medium-scale clinical cohort.
Taken together, LAD is a promising 
method, filling the need for large-scale 
gut microbiota validation tools.
MATERIALS & METHODS
Template generation for labeling 
probes labeling
We used genomic DNA extracted from 18 
different bacterial isolates for PCR ampli-
fication. These strains represented 
targets for one or more labeling probes 
(LP), thus the purpose was to use them 
for validation of specificity and reproduc-
ibility of our assay. The chosen bacteria 
were: Gemella sanguinis, Escherichia coli, 
Salmonella bongori, Salmonella enterica, 
Salmonella typhimurium, Klebsiella 
pneumoniae subsp. Pneumonae, Strepto-
coccus pyogenes, Streptococcus 
pneumoniae, Salmonella enterica subsp. 
Enterica, Bacteroides vulgatus, Bacteroides 
fragilis, Bacteroides dorei, Staphylococcus 
aureus subsp. Aureus, Staphylococcus 
aureus, Bifidobacterium breve, Bifidobac-
terium longum, Enterococcus faecalis and 
Streptococcus sanguinis.
In addition, DNA extracted from 
541 PACT (Prevention of Allergy 
Among Children in Trondheim) study 
stool samples was utilized in PCRs to 
generate the templates for LP labeling. 
These samples were collected from 
pregnant mothers and their children at 
up to several post-birth ages. Their 
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distribution was as following: 110 were 
collected from pregnant mothers, 122 from 
children up to 10 days old, 126 samples 
from 4-month-old children, 89 samples 
from 1-year-old children, and 94 from 
2-year-old children. We used gDNA that 
was already extracted. The extraction 
protocol can be found in the Materials and 
Methods section of Vebø et al. (2011) [5].
A total reaction volume of 25 μl 
comprising 1 μl bacterial lysate as a 
source of DNA template, 0.05 U HOT 
FIREPol® DNA Polymerase, 1X B1 buffer, 
2.5 mM MgCl2 (all from Solis Biodyne, 
Estonia), 0.2 mM dNTPs (Thermo Fisher 
Scientific, MA, USA), 0.2 μM sense 
primer (Mangala F-1, 5’-TCCTACGGGAG-
GCAGCAG-3’), and 0.2 μM antisense primer 
(16SUR, 5’-3’ CGGTTACCTTGTTACGACTT) 
was designed to amplify a segment of 
16S rRNA gene. PCR amplification was 
initiated with a period of 15 min at 95°C to 
activate the DNA polymerase, followed by 
30 cycles, each consisting of 30 s denatur-
ation at 95°C, 30 s annealing at 55°C and an 
80 s elongation at 72°C performed using 
an Applied Biosystems Veriti™ Thermal 
Cycler (Life Technologies, CA, USA). A 
final elongation step of 7 min at 72°C was 
also included. The amplified products were 
treated with 2.4 U of Exonuclease I (ExoI, 
Biolabs Inc., MA, USA) and 6.4 U of shrimp 
alkaline phosphatase (USB Corporation, 
OH, USA) prior to incubation at 37°C for 
120 min, and at 80°C for 15 min.
Single nucleotide extension of the LPs
A total reaction volume of 15 μl comprising 
5 μl Exo-SAP-treated template (or water as 
‘no template’ control), LPs at a final concen-
tration of 0.1 μM, 0.8 μM ddCTP-ATTO612Q 
(Jena Biosciences, Germany), 20 μM ddTTP, 
1 mM MgCl2, 1XC buffer and 0.25 U HOT 
TERMIPOL® DNA Polymerase (all from Solis 
Biodyne, Estonia) was prepared. Labeling 
reactions were performed using an Applied 
Biosystems Veriti™ Thermal Cycler, 
employing an activation step at 95°C for 
12 min, followed by 40 cycles, each 
consisting of 96°C denaturation for 20 s and 
60°C annealing/elongation for 40 s.
Melting curve analysis
5’ fluorescently labeled reporter probe(s) 
(RP) were added to the LP labeling reactions 
at a final concentration of 0.005 μM each, 
with the exception of RPs 1_1 RP ROX, 
1_2_2 RP ROX, 6_2_2 RP HEX, 6_1_4 RP 
HEX and 2_4_1 RP FAM, which had a final 
c oncentration of 0.02 μM each; reagent S, 
available from INN (Inland Norway 
University of Applied Sciences, Norway), 
was also added to a final concentration of 
0.1%. The melting curve analysis was 
performed using a 7500 Fast qPCR 
instrument (Applied Biosystems, USA) with 
the following dissociation steps: 95°C for 
15 s, 30°C for 1 min, 95°C for 15 s and 60°C 
for 15 s. Fluorescence was detected and 
expressed in dissociation curves as the 
derivative of the fluorescence versus 
temperature measurements (dF/dT) versus 
temperature (Temp.). Positive signals were 
observed as negative peaks, representing 
the abrupt, temperature-dependent drop of 
fluorescence.
Extraction of peaks & determination of 
positive signals for clinical samples
For the sake of simplicity, all data were multi-
plied by −1 since originally, positive LAD 
signals have negative values.
Fluorescence values were extracted 
from temperature measurements where 
quenching signals were expected (e.g., the 
fluorescence value at 67.7°C on HEX 
channel, where UNI probe was designed 
to quench). In addition, such values were 
extracted from 5 no template controls (NTC), 
with the aim of determining the borderline 
Figure 1.  An overview of liquid array diagnostics (LAD) method. The initial step includes PCR amplification of 16S rRNA gene, where each LP is targeted. 
If the target DNA is present, LPs become labeled with a ddCTP conjugated with a quencher molecule. Subsequently, fluorophore-labeled RPs comple-
mentary to LPs are added into the solution mix. Upon duplex formation, at a specific melting temperature, the fluorescence of the reporter decreases 
abruptly. Multiple targets can be detected in a single-tube reaction by combining different duplex melting temperatures and fluorophore colors. In the 
last step, the derivative fluorescence units (FU) are extracted from each temperature where signals are expected for further data processing. 
LP: Labeling probe; RP: Reporter probe.
btn-2018-0134.indd   144 11/03/2019   14:04
www.BioTechniques.com No. 03 | Vol. 66 | © 2019 Pranvera Hiseni 145
separating positive signals from background 
f luorescence. First, we calculated the 
distance of the observed positive signals 
from the mean background fluorescence 
using a standard Z-score. Following that, 
the margin separating the signals from the 
background was assigned to be the mean 
value of NTC plus two-times its standard 
deviation (μ+2Σ).
However, a different approach was used 
to assign positive signals for 5_1_2. Consid-
ering that there is a tight melting temper-
ature (Tm) range separating 5_1 from 
5_1_2 signals, using the above-mentioned 
formula would report false-positive signals 
for Staphylococcus (5_1_2 probe) since the 
fluorescence measurements at 55.8°C, 
where 5_1_2 is designed to quench, are 
interferingly high for each sample where 5_1 
is truly quenched (50.8°C). Thus, fluores-
cence values at 55.8°C were extracted from 
eight random samples where only 5_1 was 
observed to give signal. The mean value 
of these samples was added with three 
standard deviations (μ+3Σ), which was 
used as a margin to separate the bona fide 
Staphylococcus signals. All data values 
higher than the margins were accepted as 
positives.
Probe design
The probes, designed by Genetic Analysis 
AS [5], were used as LPs (Table 1), whereas 
the RPs were designed to be comple-
mentary to the LPs, so that they create 
duplexes that dissociate at a chosen 
temperature. Each probe has a code 
identifier (for example 1_1 for Bacteroides), 
originally used in Vebø et al. (2011) [5]. The 
Tm of the probes was calculated by the 
Oligoanalyzer 3.1 web-based bioinfor-
matics tool (Integrated DNA Technologies) 
and target Tms were achieved by varying 
the length of the RPs.
The reporter probes were designed to 
anneal to the 3’-end of each respective 
labeling probe, thus placing the fluoro-
phore, coupled to the terminal 5’nucleotide 
of the RP, in close physical proximity to the 
quencher molecule located at the 3’ end 
of the labeled LP. The list of the reporter 
probes is presented in Table 2.
Comparison of LAD-based results with 
Illumina sequencing data
87 random PACT samples (34 samples of 
children up to 10-days old, 15 of 4-month-
olds, 15 of 1-year-olds, 12 of 2-year-olds and 
11 of pregnant women) were picked to be 
sequenced with an Illumina MiSeq System 
(Illumina, CA, USA). The purpose of this step 
was to confirm the identities of samples and 
compare them with the results obtained with 
the LAD assay, by performing in silico 
labeling of the reads. In silico labeling was 
performed by textual mapping of the ‘labeled’ 
LPs to the operational taxonomic unit (OTU)
DNA sequences retrieved by Illumina, using 
the Sequence Manipulation Suite: Primer 
Map tool [6]. All OTUs that were detected by 
the same probe were grouped together and 
their number of reads was summed up for 
each sample. The total number of such reads 
was then compared with the LAD signal 
intensity for the said probe. Prior to doing 
so, LAD data were normalized so that any 
number below the cut-off value would be 
equal to zero.
To calculate the specificity and sensi-
tivity, we performed a receiver operator 
characteristic (ROC) curve analysis (MedCalc 
Software, Ostend, Belgium), which plots the 
true positive signals (as determined with 
LAD) against the false positives for different 
cut-off points (the number of Illumina reads). 
This helped find the optimum copy number 
of target sequences that can be detected 
using our method.
Table 1. Probes designed by Genetic Analysis AS for GA-map® array, used as labeling probes by liquid array 
diagnostics.
Probe identifier Taxonomic group(s) detected Probe sequence (5’–3’)
1_1 Bacteroides TTGCGGCTCAACCGTAAAATTG
1_2_2 Bacteroides (dorei, fragilis, thetaiotaomicron, vulgatus) GCACTCAAGACATCCAGTATCAACTG
2_1_min1b Gamma-proteobacteria CAGGTGTAGCGGTGAAATGCGTAGAGAT
2_3_2 Gamma-proteobacteria subgroup CGGGGATTTCACATCTGA
2_4_1 Gamma-proteobacteria subgroup TGCCAGTTTCGAATGCAGTT
4_1 Firmicutes (Lactabacillales, Clostridium perfringens, Staphylococcus) CGATCCGAAAACCTTCTTCACT
4_4_2 Enterococcus, Listeria TCCAATGACCCTCCC
4_5_2 Streptococcus pyogenes GATTTTCCACTCCCACCAT
4_6_1 Streptococcus sanguinis CACTCTCACACCCGTT
4_8_1 Streptococcus pneumoniae, Entrococcus CGCGGCGTTGCTCGGTCAGACTT
5_1 Firmucutes (Clostridia, Bacillales, Enterococcus, Lactobacillus) GGACAACGCTTGCCAC
5_1_2 Staphylococcus CGTGGCTTTCTGATTAGGTA
6_1_4 Bifidobacterium longum TGCTTATTCAACGGGTAAACT
6_2 Actinobacteria CGTAGGCGGTTCGTCGCGT
6_2_2 Bifidobacterium breve CGGTGCTTATTCGAAAGGTACACT
UNI01 16S Universal CGTATTACCGCGGCTGCTGGCA
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Subsequently, for each probe, the 
numbers of the Illumina reads lower than 
LAD detection limit were equated to zero, 
to test the correlation of the positive signals 
using Spearman’s Rho test.
Statistical analysis
Minitab Release 15.1.1.0 (Minitab Inc. 2007) 
was used to perform Student’s t-test to 
compare the differences on quenching 
strength (fluorescence mean value) between 
cohorts. For the sake of illustration, the data 
were normalized so that the cut-off value 
equals zero. In addition, the differences 
regarding the prevalence of positive signals 
were analyzed by using Pearson’s 
chi-squared test.
RESULTS & DISCUSSION
Optimization of the LAD-based  
microbiota detection assay
Based on pure cultures, we first adjusted the 
level of probes present in the reaction in 
order to achieve high signal-to-noise ratios. 
A detailed description of the experimental 
setup used in the evaluation is provided in 
Supplementary  Figures S1, S2 and S3. This 
process was performed empirically (see 
supplement for details), resulting in an assay 
that was capable of reporting 15 distin-
guishable signals in a one-tube multiplex 
reaction, consisting of probes reported in 
Table 1. The signals for each of our probes, 
besides 6_2 duplex, were at least two 
standard deviations above the average value 
of no target reactions, which represented 
the background noise (Z>2), with a 
p-value < 0.02 (Table 3).
The initial evaluation of the assay perfor-
mance was based on comparisons between 
experimental and theoretical signals, derived 
from Vebø et al. (2011) [5]. This analysis 
showed that the accuracy and specificity 
of probes was very high, reporting only the 
target strains in reactions holding individual 
bacteria or defined bacteria mixtures (Figure 
2).
Comparison of LAD-based microbiota 
assay with Illumina sequencing
To compare LAD with the output of Illumina 
sequencing, we sequenced 87 clinical 
samples, then performed in silico labeling of 
the retrieved sequences for the nine probes 
covered by the sequencing amplicon. Subse-
quently, for each probe we compared LAD 
signals with the number of sequence copies 
that acted as a template during  in silico 
labeling. Specifically, we performed ROC 
curve analysis for each probe to determine 
accuracy of classification, and to determine 
limit of detection for the LAD assay. For most 
of the probes the accuracy of detection, 
i.e. the number of correct predictions, was 
high (>80%). The detection limit for the 
probes was between 0.2 and 2%, as deter-
mined by the percentage of Illumina 
sequencing reads detected. Furthermore, 
there was a significant quantitative corre-
lation between Illumina read counts and LAD 
signals (p < 0.05), with Spearman’s rho 
ranging between 0.45 and 0.86 for all the 
probes (Table 4).
Use of LAD to genotype clinical samples
The verified assay was used to probe the 
microbiota composition from 541 PACT 
study fecal samples from infants and their 
mothers.
The highest number of positive signals 
was reported for 5_1 and 6_2_2 probe 
duplexes, designed to detect Firmicutes 
and Bifidobacterium breve, respectively. 
Overall, the results showed that in terms 
of prevalence, there is overrepresen-
tation of gammaproteobacteria and 
Enterococcus/Listeria in 4-month-old 
children, Bacteroides at 2-years old, Bifido-
bacterium at 4 months and Staphylococcus 
in 10-day-old children (Figure 3). 
Table 2. Reporter probe sequences.
Reporter probe 5’–3’ sequence
1_1 RP ROX /56-ROXN/TTTCAATTTTACGG
1_2_2 RP ROX /56-ROXN/TTTCAGTTGATACTGG
2_1_min1b RP ROX /56-ROXN/TATCTCTACGCATTTCACCGCTACA
2_3_2 RP ROX /56-ROXN/TTTCAGATGTGAAATCCC
4_1 RP CY5 /5CY5/TTTAGTGAAGAAG
4_5_2 RP CY5 /5CY5/TATGGTGGGAGT
4_8_1_RP2_CY5 /5CY5/TAAGTCTGACCGAGCAACGCCGC
4_6_1 RP CY5 /5CY5/TTAACGGGTGTGAGAGTG
2_4_1 RP FAM /56-FAM/TAACTGCATTC
4_4_2 RP FAM /56-FAM/TTTGGGAGGGTCAT
5_1 RP FAM /56-FAM/TTTGTGGCAAGCGTTG
5_1_2 RP FAM /56-FAM/TTACCTAATCAGAAAGCCACG
6_2 RP HEX /5HEX/TTTTACGCGACG
6_2_2 RP HEX /5HEX/TTAGTGTACCTTTCG
6_1_4 RP HEX /5HEX/TTAGTTTACCCGTTGAAT
UNI01 RP HEX /5HEX/TTGCCAGCAGCCGCGGTAATACG
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The signal strength for S. pyogenes and 
S. sanguinis had a peak in 1-year-old children, 
while the strongest signals for S. pneumoniae 
were in 10-day-old children.
There was no significant change in 
prevalence for the probe detecting a group 
of species within Firmicutes (5_1 probe, 
detecting for Clostridia, Bacillales, Entero-
coccus and Lactobacillus); however, the 
signal strength showed an increase parallel 
with age. The opposite was observed for 
the other Firmicutes probe, 4_1 (detecting 
for Lactobacillus, C. perfringens and Staph-
ylococcus), which had a decrease both on 
prevalence and signal strength in older 
children.
Use of LAD for rapid detection of 
microbial communities
Here we present LAD, a novel technique that 
combines single-nucleotide-extension of the 
probes with HRM analysis. Compared with 
existing tools for microbiome testing, 
LAD-based tests are simpler to perform, are 
cheaper as they do not require expensive 
instrumentation and reagents, and yield 
results faster, within a working day.
Our method does not require a dedicated 
instrument that would solely be used for 
LAD-based tests. It requires real-time 
PCR instrumentation, which is widely and 
commonly used in most laboratories. In 
comparison with other real-time PCR-based 
approaches, it offers a higher level of 
m ultiplexity per well, few reagents and 
short hands-on time, satisfying the actual 
need of detecting a relatively low number 
of markers (<50) in a very large number of 
samples.
LAD represents a highly reproducible 
method. Initially, the designed probes 
undergo a process of validation for their 
specificity, which ensures that all probes 
become labeled only when their target 
is present in the reaction. Further on, 
each labeled probe is tested to ensure it 
hybridizes only with its corresponding 
Table 3. Probe signal-to-noise ratios.
Probe Average of positive signals (μ1)
Average of NT  
signals (μ2)
NT standard  
deviation (Σ) Z-score((μ1 - μ2)/ Σ) p-value
6_2 −287.5 70.4 87.9 −4.1 >0.99
UNI01 1704.1 −331.1 58.2 34.9 <0.0002
6_2_2 723.8 −91.2 121.8 6.7 <0.0002
6_1_4 2022.9 −7.2 95.9 21.2 <0.0002
4_1 −537.4 −2599.6 896.6 2.3 0.01
4_5_2 −446.3 −2398.5 826.1 2.3 0.01
4_6_1 −364.9 −2013.9 816.4 2.0 0.02
4_8_1† N/D   N/D N/D
1_1 2062.9 −569.1 421.3 6.2 <0.0002
1_2_2 2010.5 −336.4 106.5 22.0 <0.0002
2_3_2 2230.5 −326.5 234.0 10.9 <0.0002
2_1_min1b 1865.0 −473.9 83.4 28.0 <0.0002
2_4_1 117.9 −836.5 365.8 2.6 0.0047
4_4_2 1251.5 −801.7 198.5 10.3 <0.0002
5_1 1355.9 −1021.1 109.9 21.6 <0.0002
5_1_2 2286.7 −515.5 520.8 5.4 <0.0002
†The fluorescence values for 4_8_1 probe duplex were not determinedbecause we lacked the DNA template.
N/D: No data; NT: No template.
 
Figure 2.  Evaluation of LAD probe accuracy and sensitivity. All signals that were at least two 
standard deviations away from the background fluorescence were accepted as positives. Tests on 
individual bacterial strains or defined mixtures of bacteria showed identical results for the correct 
targets on both platforms, GA-map® (left) and LAD (right). No false-positive signals, reporting 
nontargets, were registered with LAD.
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reporter probe, thus avoiding false-
positive signals being generated in the 
presence of a nontarget probe.
The addition of a synthetic quencher-
and-fluorophore-labeled duplex (designated 
Tm and detection channel) into the master 
mix will provide the basis for a well-to-well 
data normalization, ensuring reproducibility.
For this study, we chose to adopt probes 
designed by Genetic Analysis AS [5], consid-
ering that their platform, GA-map, is an 
already validated method based on single 
nucleotide extension. Results obtained with 
GA-map served as a reference and allowed 
us to evaluate the overall performance of 
LAD. We found highly comparable probe 
specificities using the two technologies, 
suggesting the transferability of GA-map 
probes to LAD detection.
Our results on the clinical dataset show 
that there is a rapid decrease of staphy-
lococci from 10-day- to 4-month-old 
children, and a peak of bifidobacteria at 
the age of 4 months, which is in full accor-
dance with the previous findings made 
with GA-map [5]. However, we identified 
a peak of Bacteroides in 2-year-old 
children, whereas Vebø et al. (2011) [5] 
found that Bacteroides were overrepre-
sented in 4-month-old children. This may 
be explained by the fact that we did not 
test an identical set of samples, since an 
increase of Bacteroides in older children 
has already been described from many 
other papers in the literature [7,8].
In addition, we compared our assay with 
the outcome of Illumina MiSeq sequencing, 
which demonstrated a high classification 
accuracy and low detection limit for 
LAD, providing evidence of its sensitivity. 
The quantitative comparisons, however, 
showed some more deviations between 
the two platforms. Unfortunately, we could 
not Illumina-sequence the ∼1200 bp PCR 
fragment analyzed with LAD due to the 
300-bp limitation in Illumina read-length 
chemistry, which could potentially explain 
the differences between the two sets of 
results.
Numerous gut microbial markers that 
are linked with many disorders such as 
obesity [9–11], diabetes [11–13], multiple 
sclerosis [14,15] or irritable bowel syndrome 
[1,16] have already been described, but 
these have not yet been clinically validated 
in large-scale multicenter studies. With its 
main advantage of being very cheap, rapid 
Table 4. Evaluation of the diagnostic ability of liquid array diagnostics-based tests.
Probe 2_4_1 5_1 5_1_2 1_1 1_1_2 2_3_2 2_1_min1b 4_1 4_8_1
Detection limit (%) 0.8 0.4 1.2 2.4 0.1 1.1 0.4 0.022 0.002
Sensitivity (%) 90 91.9 93.3 84.8 82 85 65.5 62.7 69.2
Specificity (%) 92.1 76.9 95.8 91.7 65.5 83 86.2 85.7 68.9
Spearman’s Rho 0.74 0.82 0.86 0.81 0.57 0.72 0.66 0.65 0.45
Figure 3. Signal strength and prevalence of positive signals. Significant differences, that here are depicted with *, were observed between groups for 
most of the probes.
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and simple, in addition to being an accurate 
method, LAD will offer this possibility.
We acknowledge the limitations of 
our method regarding systems where the 
microbiome composition is complex, unpre-
dictable and constantly shifting. Building 
a LAD assay de novo is best conducted in 
systems with relatively low complexity, 
where the knowledge regarding the micro-
biome composition is already described, 
such as is the case with gut microbiota. A 
well-defined composition is a prerequisite 
towards designing targeting probes.
Here, we used 15 different probe 
duplexes, which were designed to utilize four 
channels of detection and at least three Tms 
per channel. By using a qPCR machine with 
six channels of detection and exploiting at 
least six resolvable Tms per channel, the 
multiplex level can be elevated to at least a 
36-plex. Thus, the possibility of multiplexing 
is limited by the instrument, and not by LAD 
technology in itself.
In conclusion, we believe LAD will fulfill 
the need for assays able to detect up to 
50 biomarkers, where high throughput is 
essential. This will particularly relate to 
human gut microbiota markers related to 
health and disease.
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